

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2023	Preceding 3 months ended 31.03.2023	Corresponding 3 months ended 30.06.2022	Year ended 31.03.2023
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 4)
	Continuing operations				
	Income				
1	Revenue from operations	73802	78216	72946	321634
2	Other income	3680	2797	2779	10152
3	Total Income (1+2)	77482	81013	75725	331786
	Expenses				
	(a) Cost of materials consumed	14547	9570	13814	39435
	(b) Purchases of stock-in-trade	17420	17779	27160	78843
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(4438)	6934	(13686)	6725
	(d) Employee benefits expense	16500	14884	15122	59499
	(e) Finance costs	28	65	68	181
	(f) Depreciation and amortisation expense	1636	1718	1582	6577
	(g) Other expenses	15648	12373	15743	57191
4	Total expenses	61341	63323	59803	248451
5	Profit before exceptional items and tax (3-4)	16141	17690	15922	83335
6	Exceptional items [credit/(charge)] (Refer Note 3)	1730	1040	-	(97)
7	Profit before tax (5+6)	17871	18730	15922	83238
8	Tax expense				
	(a) Current tax	5263	5658	4706	24605
	(b) Deferred tax	(450)	(76)	(347)	(1837)
9	Profit for the period/year from continuing operations (7-8)	13058	13148	11563	60470
	Discontinued operations				
10	Profit before tax from discontinued operations (Refer Note 4)	-	-	413	413
11	Tax expense of discontinued operations (Refer Note 4)	-	-	108	108
12	Profit from discontinued operations after taxes (10-11)	-	-	305	305
13	Profit for the period (9+12)	13058	13148	11868	60775

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2023	Preceding 3 months ended 31.03.2023	Corresponding 3 months ended 30.06.2022	Year ended 31.03.2023
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 4)
14	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss	-	(180)	-	(807)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	45	-	203
15	Total comprehensive income for the period (13+14)	13058	13013	11868	60171
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
	Other equity				158359
	Earnings per share (EPS) (of Rs. 10 each) (for continuing operations)				
	Basic and diluted EPS before Exceptional items (Rs.)	6.94	7.28	6.83	35.72
	Basic and diluted EPS after Exceptional items (Rs.)	7.71	7.77	6.83	35.70
	Earnings per share (EPS) (of Rs. 10 each) (for discontinued operations)				
	Basic and diluted EPS for discontinued operations (Rs.)	-	-	0.18	0.18
	Earnings per share (EPS) (of Rs. 10 each) (for continuing and discontinued operations)				
	Basic and diluted EPS before Exceptional items (Rs.)	6.94	7.28	7.01	35.90
	Basic and diluted EPS after Exceptional items (Rs.)	7.71	7.77	7.01	35.88
		Not Annualised			

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26th July, 2023. The Statutory Auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June, 2023.
2. The figures for the 3 months ended 31st March, 2023 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March, 2023.
3. Exceptional items credit for the quarter ended 30th June, 2023 of Rs.1730 lakhs (Quarter ended 31st March, 2023 Rs. 1040 lakhs) is on account of profit on sale of surplus residential properties. Exceptional items charge for the year ended 31st March, 2023 of Rs.97 lakhs comprises of profit on sale of surplus residential properties Rs. 964 lakhs; additional charge of Rs. 1137 lakhs on account of restructuring of the commercial functions and other reversals credit of Rs. 76 lakhs.
4. The Board of Directors of the Company had approved the transfer of the trademarks pertaining to 'Iodex' and 'Ostocalcium' brands ("Brands") in India along with legal, economic, commercial and marketing rights of such brands and other identified assets to GlaxoSmithKline Asia Private Limited during the year ended 31st March, 2022. Consequently, the transfer of brands and profits arising from sale of products as per the terms of contract had been disclosed as Discontinued Operations in accordance with Ind AS 105 "Non-Current Assets Held for Sale and Discontinued Operations".
5. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
6. Previous periods' figures have been re-grouped / re-classified wherever necessary.

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346

26th July, 2023

